Clinical Trials Logo

Heart Failure clinical trials

View clinical trials related to Heart Failure.

Filter by:

NCT ID: NCT02884206 Completed - Clinical trials for Chronic Heart Failure (CHF)

Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction

PERSPECTIVE
Start date: November 23, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effect of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction. Cognitive function will be assessed using a comprehensive battery of tests with an evaluation of longitudinal change of cognitive domains including memory, executive function, and attention.

NCT ID: NCT02880683 Completed - Cardiac Output, Low Clinical Trials

Cardiac Output Autonomic Stimulation Therapy for Heart Failure (COAST-HF) - Human NeuroCatheter Study

COAST-HF HNrCS
Start date: October 2015
Phase: N/A
Study type: Interventional

A single-center feasibility study in patients undergoing cardiac catheterization, to investigate the acute hemodynamic effects of transvenous cardiac autonomic nerve stimulation.

NCT ID: NCT02877446 Completed - Clinical trials for Chronic or Acute Advanced Heart Failure

South Of France Cardiac Assist Registry

SOFCAR
Start date: January 2016
Phase:
Study type: Observational

Chronic heart failure is a common disease. It is also a serious disease with a mortality of 50% at 5 years, representing a significant cost in terms of public health expenditure. Heart transplantation represents the "gold standard" of care for terminal heart failure patients reached the end of the disease despite optimal medical and surgical management of their disease, with a survival rate of transplant patients by 90% at 1 year and 82% at 3 years. Long term LVAD are an innovative technology available for more than a decade, developed in part because of the shortage of cardiac grafts and high mortality among patients waiting for transplants due to an important pending. This technique is used substantially only for ten to fifteen years in the world. Survival after implantation of latest devices reaches 80% at 1 year. In France, this technique is intended for patients with terminal heart failure who ended different pharmacological and invasive therapeutic resources available. Currently, academic centers that offer the possibility of long-term LVAD support are organized unicentric in order to centralize specialized care for these patients. Indeed, patients candidates for the establishment of a long-term LVAD are rigorously selected to ensure an acceptable survival. However, practices vary considerably from one center to another in particular regarding: - Implantation indications, - Pre-implantation patient assessment, - Monitoring, - Implementation of pharmacological treatments, particularly anticoagulants or betablockers.

NCT ID: NCT02877095 Completed - Acute Heart Failure Clinical Trials

Subcutaneous Furosemide in Acute Decompensated Heart Failure Pilot

SUBQ-Pilot
Start date: December 19, 2016
Phase: Phase 1
Study type: Interventional

The Pilot study is designed to evaluate the overall safety and feasibility of a strategy based on subcutaneous delivery of furosemide. It will be used to inform the subsequent evaluation phase of the study (separate protocol). The primary objective of the study is to determine if a strategy of a novel subcutaneous delivery of furosemide is safe and feasible in patients with acute heart failure.

NCT ID: NCT02874794 Completed - Clinical trials for Heart Failure and Reduced Ejection Fraction

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction

EVALUATE-HF
Start date: August 17, 2016
Phase: Phase 4
Study type: Interventional

To determine whether treatment with sacubitril/valsartan provides a superior effect on aortic characteristic impedance compared to enalapril in patients with heart failure and reduced ejection fraction (left ventricular ejection fraction [LVEF] ≤ 40%) after 12 weeks of treatment. The primary endpoint is the change in aortic characteristic impedance (Zc = dP/dQ in early systole) between baseline and Week 12.

NCT ID: NCT02873169 Completed - Clinical trials for Severe Cardiac Insufficiency

Determination of Risk Factors of Ventricular Arrhythmias (VAs) After Implantation of Continuous Flow Left Ventricular Assist Device With Continuous Flow Left Ventricular Assist Device (CF-LVAD)

ASSIST-ICD
Start date: September 2015
Phase: N/A
Study type: Observational

Determination of risk factors of ventricular arrhythmias (VAs) after implantation of continuous flow left ventricular assist device in order to characterize which patient requires ICD implantation in primary prevention.

NCT ID: NCT02869022 Completed - Heart Failure Clinical Trials

Study of Organ Perfusion With Custodiol-N Solution Compared With Custodiol Solution in Heart Transplantation

Start date: July 2016
Phase: Phase 3
Study type: Interventional

The objective of this investigation is to demonstrate non-inferiority in outcome of Custodiol-N against Custodiol in heart transplantation.

NCT ID: NCT02865525 Completed - Heart Failure Clinical Trials

Development and Validation of a Self-administered QUestionnaire to Identify Levers of Adhesion Behavior to Patient's Medication in Order to Adapt the Educational Monitoring.

QUILAM
Start date: March 2013
Phase:
Study type: Observational [Patient Registry]

Medication non-adherence is an economic problem and a major public health challenge. Factors influencing medication adherence can be modelled according to five dimensions: disease, medication, patient and its close relatives, demographic and socioeconomic factors and health care system. A tool is needed to qualify medication adherence in order to adapt tailored support for individual patients to promote and optimize adherence to therapy. The objective of this work is to present the preliminary results of QUILAM project which is divided into 3 phases: 1. Development of a tool to assess barriers to medication adherence in chronic patient (COPD, Heart failure, Type 2 diabetes) ; 2. Validation of the instrument (especially against clinical criteria) ; 3. Evaluation of the sensitivity of the tool during educational interventions.

NCT ID: NCT02864420 Completed - Heart Failure Clinical Trials

Hospitalization at Home: The Acute Care Home Hospital Program for Adults

Start date: September 2016
Phase: N/A
Study type: Interventional

The investigators propose a home hospital model of care that substitutes for treatment in an acute care hospital. Limited studies of the home hospital model have demonstrated that a sizeable proportion of acute care can be delivered in the home with equal quality and safety, reduced cost, and improved patient experience.

NCT ID: NCT02863796 Completed - Heart Failure Clinical Trials

Safety and Feasibility of the WhiteSwell System"

SWIFTHF
Start date: August 1, 2016
Phase: N/A
Study type: Interventional

Early feasibility study to evaluate safety and performance of the WhiteSwell System in the treatment of fluid overload in hospitalized patients with acutely decompensated heart failure.